TScan Therapeutics, Inc. (TCRX)
NASDAQ: TCRX · Real-Time Price · USD
1.260
-0.050 (-3.82%)
At close: Apr 28, 2026, 4:00 PM EDT
1.320
+0.060 (4.76%)
Pre-market: Apr 29, 2026, 7:30 AM EDT
TScan Therapeutics Revenue
In the year 2025, TScan Therapeutics had annual revenue of $10.33M with 266.65% growth. TScan Therapeutics had revenue of $2.57M in the quarter ending December 31, 2025, with 286.02% growth.
Revenue (ttm)
$10.33M
Revenue Growth
+266.65%
P/S Ratio
7.33
Revenue / Employee
$72,711
Employees
142
Market Cap
75.73M
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionTCRX News
- 1 day ago - TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 29th Annual Meeting - GlobeNewsWire
- 13 days ago - TScan Therapeutics Transcript: 25th Annual Needham Virtual Healthcare Conference - Transcripts
- 21 days ago - TScan Therapeutics to Participate in the 25th Annual Needham Virtual Healthcare Conference - GlobeNewsWire
- 7 weeks ago - TScan Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference - Transcripts
- 2 months ago - TScan Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - GlobeNewsWire
- 2 months ago - TScan Therapeutics Completes Enrollment in Cohort C of Phase 1 ALLOHA™ Trial and Announces FDA Clearance of Investigational New Drug Applications for Heme Candidates TSC-102-A01 and TSC-102-A03 - GlobeNewsWire
- 2 months ago - TScan Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference - GlobeNewsWire
- 5 months ago - TScan Therapeutics Transcript: KOL Event - Transcripts